PerDUCing results
This article was originally published in The Gray Sheet
Executive Summary
Comedicus, Inc. will submit data to FDA from a 20-patient study of the PerDUCER by year-end to secure 510(k) clearance for the pericardial access device. The Columbia Heights, Minnesota company plans to develop electrophysiology mapping and ablation, drug delivery and MRI applications capitalizing on the PerDUCER's potential ability to provide minimally invasive intrapericardial guidewire access to the heart's external walls. However, the privately-held firm anticipates being acquired before those indications are developed...